<- Go Home
Panamed Corp.
As of July 14, 2005, Panamed Corporation was acquired by Visual Board Books, Inc. in a reverse merger transaction. Panamed Corporation engages in the bio-tech industry, with a primary focus on testing and distributing a patented line of therapeutics offered by Havel Investments Limited. The therapeutics are used for treating serious illness, such as HIV/AIDS, herpes, shingles, cancer, ALS, lupus, Parkinson's Disease, rheumatoid arthritis, and multiple sclerosis. The company has an exclusive license to test and distribute Havel's treatments for HIV/AIDS within the continent of Africa. Viro-Net is the name given to Havel's product for treating HIV/AIDS, Herpes Simplex 1, Herpes Simplex 2, and Shingles. The therapeutics can be described as an immuno-modulating biological compound, which can be used to target the virus for elimination by the body's own immune system.
Market Cap
$2.5M
Volume
N/A
Cash and Equivalents
$106.00
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.16
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
10.17
Price / Earnings
-8.82
Price / Tangible Book Value
10.17
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$163.0K
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$106.00
Debt
$7.4K
Equity
$194.2K
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A